Locoregional recurrence and mortality after breast cancer surgery in patients aged 85 and older.

IF 3.3 3区医学 Q2 ONCOLOGY

Breast Cancer Research and Treatment Pub Date : 2026-08-06 DOI:10.1007/s10549-026-08044-x

David Foulad, Jacqueline Tsai, Ingrid Luo, Adele Xu, Mina Satoyoshi, Su-Ying Liang, Pragati Kenkare, Summer Han, Allison W Kurian, Irene L Wapnir

{"title":"Locoregional recurrence and mortality after breast cancer surgery in patients aged 85 and older.","authors":"David Foulad, Jacqueline Tsai, Ingrid Luo, Adele Xu, Mina Satoyoshi, Su-Ying Liang, Pragati Kenkare, Summer Han, Allison W Kurian, Irene L Wapnir","doi":"10.1007/s10549-026-08044-x","DOIUrl":null,"url":null,"abstract":"Purpose: Life expectancy is increasing and the number of patients age ≥ 85 with breast cancer (BC) may be on the rise. We report descriptive statistics regarding surgical management and outcomes in this cohort.Methods: Patients ≥ 85 years surgically treated for a primary or in-breast tumor recurrence (IBTR) were identified through Oncoshare, a database that links Stanford Healthcare and Sutter Health electronic medical records with the California Cancer Registry.Results: From 2010 to 2019, 91 patients, 65 (71%) aged 85-89 and 26 (29%) ≥ 90 + years were identified. 29.2% were screen-detected compared to 57.7% with a prior BC. Lumpectomy was performed in 70% of 96 cancers, nodal staging in 36% of lumpectomies and 91% of mastectomies. Locoregional recurrences (LRR) occurred in 18 patients, 17 after lumpectomy and two BC-related deaths. BC-specific survival was 100.0% at 3 years and 98.0% (95%CI: 94.3%-100.0%) at 5 years. Overall survival (OS) was 77.9% (95% CI: 68.8%-88.1%) at 3 years and 59.9% (95% CI: 49.3%-72.6%) at 5 years. Five-year OS was 71.9% (95% CI: 60.4%-85.6%) for those 85-89 years vs. 28.3% (95% CI: 13.6%-58.6%) for those ≥ 90 years, (p < 0.001). Life expectancy, estimated as median OS, was 7.6 (85-89)and 3.5 (> 90) years. The cumulative incidence of LRR was 4.6%(95% CI: 2.2-9.0%) at 3 years and 13.4%(95% CI: 5.9-20.8%) at 5 years, factoring death as a competing risk using the Aalen-Johansen estimator.Conclusion: Surgery achieves satisfactory local control of disease in patients ≥ 85 years with a new BC or IBTR.","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"218 3","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-026-08044-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Life expectancy is increasing and the number of patients age ≥ 85 with breast cancer (BC) may be on the rise. We report descriptive statistics regarding surgical management and outcomes in this cohort.

Methods: Patients ≥ 85 years surgically treated for a primary or in-breast tumor recurrence (IBTR) were identified through Oncoshare, a database that links Stanford Healthcare and Sutter Health electronic medical records with the California Cancer Registry.

Results: From 2010 to 2019, 91 patients, 65 (71%) aged 85-89 and 26 (29%) ≥ 90 + years were identified. 29.2% were screen-detected compared to 57.7% with a prior BC. Lumpectomy was performed in 70% of 96 cancers, nodal staging in 36% of lumpectomies and 91% of mastectomies. Locoregional recurrences (LRR) occurred in 18 patients, 17 after lumpectomy and two BC-related deaths. BC-specific survival was 100.0% at 3 years and 98.0% (95%CI: 94.3%-100.0%) at 5 years. Overall survival (OS) was 77.9% (95% CI: 68.8%-88.1%) at 3 years and 59.9% (95% CI: 49.3%-72.6%) at 5 years. Five-year OS was 71.9% (95% CI: 60.4%-85.6%) for those 85-89 years vs. 28.3% (95% CI: 13.6%-58.6%) for those ≥ 90 years, (p < 0.001). Life expectancy, estimated as median OS, was 7.6 (85-89)and 3.5 (> 90) years. The cumulative incidence of LRR was 4.6%(95% CI: 2.2-9.0%) at 3 years and 13.4%(95% CI: 5.9-20.8%) at 5 years, factoring death as a competing risk using the Aalen-Johansen estimator.

Conclusion: Surgery achieves satisfactory local control of disease in patients ≥ 85 years with a new BC or IBTR.

查看原文本刊更多论文

85岁及以上乳腺癌手术后的局部复发和死亡率。

目的：预期寿命增加，年龄≥85岁的乳腺癌（BC）患者数量可能呈上升趋势。我们报告了该队列中关于手术处理和结果的描述性统计数据。方法：通过Oncoshare（一个将Stanford Healthcare和Sutter Health的电子医疗记录与加州癌症登记处联系起来的数据库）确定≥85年手术治疗的原发性或乳腺肿瘤复发（IBTR）患者。结果：2010 - 2019年共发现91例患者，其中65例（71%）年龄在85-89岁之间，26例(29%)≥90岁以上。29.2%的患者通过筛查被发现，而先前有BC的患者为57.7%。96例肿瘤患者中有70%进行了乳房肿瘤切除术，36%的肿瘤患者和91%的乳房切除术患者进行了淋巴结分期。18例患者发生局部复发（LRR），其中17例发生在乳房肿瘤切除术后，2例bc相关死亡。3年和5年的bc特异性生存率分别为100.0%和98.0% （95%CI: 94.3%-100.0%）。3年总生存率（OS）为77.9% (95% CI: 68.8%-88.1%)， 5年总生存率为59.9% （95% CI: 49.3%-72.6%）。85-89岁患者的5年OS为71.9% (95% CI: 60.4%-85.6%)，≥90岁患者的5年OS为28.3% (95% CI: 13.6%-58.6%) （p < 90）年。LRR的累积发病率在3年时为4.6%(95% CI: 2.2-9.0%)，在5年时为13.4%(95% CI: 5.9-20.8%)，使用aallen - johansen估计器将死亡作为竞争风险因素考虑在内。结论：对于≥85岁的新发BC或IBTR患者，手术可获得满意的局部疾病控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Research and Treatment 医学-肿瘤学

CiteScore

6.80

自引率

2.60%

发文量

342

审稿时长

1 months

期刊介绍： Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.